Content deleted Content added
Tags: Mobile edit Mobile web edit |
|||
(30 intermediate revisions by 23 users not shown) | |||
Line 1: {{short description|Chemical compound}} {{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = | IUPAC_name = 2-''sec''-Butyl-2-methylpropane-1,3-diyl dicarbamate | image = Mebutamate.svg Line 16 ⟶ 17: | legal_US = Schedule IV | legal_status = | routes_of_administration = <!--Pharmacokinetic data--> Line 23 ⟶ 24: | metabolism = | elimination_half-life = | excretion = <!--Identifiers--> | CAS_number_Ref = {{cascite| | CAS_number = | ATC_prefix = N05 | ATC_suffix = BC04 Line 33 ⟶ 34: | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = | UNII_Ref = {{fdacite| | UNII = 5H8F175RER | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = D01807 | ChEMBL_Ref = {{ebicite|changed|EBI}} | ChEMBL = | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID = 5919 <!--Chemical data--> | C=10 | H=20 | N=2 | O=4 | smiles = CCC(C)C(C)(COC(=O)N)COC(=O)N
| StdInChI_Ref = {{stdinchicite|changed|chemspider}} | StdInChI = 1S/C10H20N2O4/c1-4-7(2)10(3,5-15-8(11)13)6-16-9(12)14/h7H,4-6H2,1-3H3,(H2,11,13)(H2,12,14) | StdInChIKey_Ref = {{stdinchicite|changed|chemspider}} | StdInChIKey = LEROTMJVBFSIMP-UHFFFAOYSA-N }}
'''Mebutamate''' ('''Capla''', '''Dormate''') is an [[anxiolytic]] and [[sedative]] [[drug]] with [[antihypertensive]] effects of the carbamate class.<ref name="TaylorFrancis2000">{{cite book | title = Index Nominum 2000: International Drug Directory | url = https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA634 | date = January 2000 | publisher = Taylor & Francis | isbn = 978-3-88763-075-1 | page = 634}}</ref><ref>{{ cite book | title = The Merck Index | edition = 14 | publisher = Merck Publishers | isbn = 978-0-911910-00-1 | at = 5813 | date = 2006-11-03 }}</ref> It has effects comparable to those of [[barbiturate]]s such as [[secobarbital]], but is only around 1/3 the potency of secobarbital as a sedative. Side effects include [[dizziness]] and [[headaches]].<ref>{{cite journal | vauthors = Tetreault L, Richer P, Bordeleau JM | title = Hypnotic properties of mebutamate: a comparative study of mebutamate, secobarbital and placebo in psychiatric patients | journal = Canadian Medical Association Journal | volume = 97 | issue = 8 | pages = 395–8 | date = August 1967 | pmid = 6037393 | pmc = 1923261 }}</ref> Mebutamate is one of many [[Gabaergic|GABAergic]] drugs which act via [[allosteric]] agonism of the [[GABAA receptor|GABA<sub>A</sub> receptor]] at the β-subreceptor similar to barbiturates. In contrast, [[benzodiazepines]] act at the α-subreceptor. As such, carbamates and barbiturates, possess [[analgesic]] properties while the benzodiazepine class of drugs are strictly psychoactive. Other carbamates with the same mechanism of action and pharmacological properties include [[meprobamate]], [[carisoprodol]], [[felbamate]], and [[tybamate]]. ==Synthesis== [[File:Mebutamate synthesis.svg|thumb|center|700px|Mebutamate synthesis: Berger, Ludwig, {{US patent|2878280}} (1959 to [[Carter-Wallace|Carter Prod]].).]] ==Structural analogs== *[[Lorbamate]] *[[Carisoprodol]] *[[Pentabamate]] *[[Meprobamate]] *[[Felbamate]] *[[Tybamate]] == References == {{ {{Anxiolytics}} {{GABAAR PAMs}} [[Category:Anxiolytics]] [[Category:Carbamates]] [[Category:GABAA receptor positive allosteric modulators]] {{sedative-stub}}
|